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Ultraviolet radiation (UV) contributes to a variety of skin diseases including inflammation, degenerative aging, and cancer.
Historically, humans have been exposed to UV radiation mainly through occupational exposure; recreational UV exposure,
however, has increased dramatically in recent years, because of outdoor leisure activities and to purposely tan for cosmetic purposes.
Both UVB and UVA radiation have been shown to cause DNA damage and immunosuppression, the important forms of biological
damage that lead to NMSC. Nonmelanoma skin cancer (NMSC) is themost commonmalignancy, whose public health significance
is often unrecognized which continues to grow at an alarming rate, becoming an occupational disease. Available treatments
alternative to surgery include photodynamic therapy, electrochemotherapy, cryotherapy, ablative lasers, 5-fluorouracil, imiquimod,
ingenolmebutate, and diclofenac. Among these, photodynamic therapy is a noninvasive techniquewith excellent cosmetic outcome
and good curative results, when used in initial stages of skin cancers for superficial lesions. It is administered under numerous and
significantly varied regimens and there are a wide range of cure rates reported, permitting treatment of large and multiple lesions
with excellent cosmetic results. This is an overview of photodynamic applications especially for the treatment of NMSC, with a
short focus on daylight modality.
1. Introduction
UV energy can be subdivided into UV-A, UV-B, and UV-C
components based on electrophysical properties, with UV-
C photons having the shortest wavelengths (100–280 nm)
and highest energy, UV-A having the longest (315–400 nm),
but least energetic photons, and UV-B falling in between.
Each component of UV can exert a variety of effects on
cells, tissues, and molecules. Not surprisingly, skin cancer
risk generally mirrors this geographic pattern, particularly
among fair-skinned sun-sensitive persons.One of the greatest
risk factors for the development of cutaneous melanoma is
having a fair skin complexion, which is characterized by
low levels of a UV-blocking dark pigment called eumelanin
in the epidermis. Individuals with light skin pigmentation
suffer comparatively more skin damage from UV, because it
is relatively easy for UV rays to penetrate the epidermis to
damage both keratinocytes and melanocytes in the deeper
layers of the epidermis. Fair-skinned individuals are exposed
to higher-realized doses of UV radiation in the skin and UV-
induced mutations, which directly contribute to melanoma
and other forms of skin cancer, accumulating over time.
Much UV-induced pathology, including skin cancer, can be
avoided by minimizing UV exposure [1].
Nonmelanoma skin cancer (NMSC) is the most com-
mon malignancy, whose public health significance is often
unrecognized. They comprise more than one-third of all
cancers and are increasing worldwide, causing a significant
economic burden at the individual and community levels.
The most common NMSCs are basal cell carcinoma (BCC)
and squamous cell carcinoma (SCC), occurring at a ratio
of about 4 : 1 and accounting for about 90% of all skin
cancers diagnosed globally. As these cancers are not reported
to cancer registries in most countries, precise statistics are
generally not available. However, it is estimated that between
two and three million people are diagnosed worldwide each
year, with an average annual increase of 3% to 8% in white
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populations in Australia, Europe, United States, and Canada
over the last 30 years. The global incidence rates vary by
skin complexion and geographical region and are expected to
continue to rise in the coming years, due to growing exposure
to ultraviolet (UV) sunlight associated with increased sun-
seeking behaviors and depletion of stratospheric ozone. Phe-
notype characteristics, environmental exposures, and genetic
predisposition appear to be risk factors for their development
and progression. Early detection through established meth-
ods or newer technologies is critical for reducing both skin
cancer mortality and the overall skin cancer burden [1, 2].
2. Photodynamic Therapy
Topical photodynamic therapy (PDT) broadband red light
source 570–670 nm is acknowledged to be an effective and
safe treatment for NMSCs with favorable cosmetic outcomes.
PDT involves the topical application of a photosensitizer,
5-aminolevulinic acid (ALA), or its methyl ester-methyl
aminolevulinate (MAL) which are precursor of the endoge-
nous photosensitizer Protoporphyrin IX and subsequent
illumination of the skin lesion with light of the appropriate
wavelength. In Europe, currently, only MAL is approved for
the treatment of AKs, but it is significantly more expensive
than ALA and therefore ALA is being used widely off
label. It is a useful nonsurgical treatment option for actinic
keratosis (AK), basal cell carcinoma (BCC), and in situ
squamous cell carcinoma (Bowen disease), especially at sites
that are cosmetically sensitive or prone to impaired wound
healing [3]. It is a rapidly evolving form of phototherapy
using nontoxic light-sensitive compounds that are exposed
selectively to light, whereupon they become toxic to targeted
malignant and other diseased cells, and it has proven ability
to kill microbial cells, including bacteria, fungi and viruses
(warts and molluscum contagiosum). It is used clinically to
treat a wide range of medical conditions, including acne, skin
aging, psoriasis, granuloma annulare, age-related macular
degeneration and malignant cancers, CTCL, and extramam-
mary Paget disease and is recognized as a treatment strategy
which is both minimally invasive and minimally toxic [4–
7]. The combination of photosensitizer, a light source and
tissue oxygen, leads to the chemical destruction of any tissues
which have either selectively taken up the photosensitizer
or have been locally exposed to light, with recruitment of
inflammatory cells, increased immune response, and vascular
compromise. Single oxygen can also destroy photosensitizing
agent itself preventing further action, a process referred
to as photobleaching. The wavelength of the light source
needs to be appropriate for exciting the photosensitizer
to produce reactive oxygen species. These reactive oxygen
species generated through PDT are free radicals (Type I
PDT) generated through electron abstraction or transferred
from a substrate molecule and highly reactive state of oxygen
known as singlet oxygen (Type II PDT). In understanding the
mechanismof PDT it is important to distinguish it fromother
light-based and laser therapies such as laser wound healing
and rejuvenation, or intense pulsed light hair removal, which
do not require a photosensitizer [3, 8].
3. History
While the applicability and potential of PDT have been
known for over a hundred years, the development of modern
PDT has been a gradual one, involving scientific progress in
the fields of photobiology and cancer biology, as well as the
development of modern photonic devices, such as lasers and
LEDs. John Toth, in 1981, acknowledged the “photodynamic
chemical effect” of the therapy and wrote the first “white
paper” branding the therapy as “Photodynamic Therapy”
(PDT). PDT received even greater interest as result ofThomas
Dougherty helping expand clinical trials and forming the
International Photodynamic Association, in 1986 [3, 9].
4. PDT in Ancient Medicine
The earliest recorded treatments that exploited a photosen-
sitizer and a light source, in this case sunlight, for medical
effect can be found in ancient Egyptian and Indian sources.
Annals over 3000 years report the use of topically applied
vegetable and plant substances to produce photoreactions in
skin and cause a repigmentation of depigmented skin lesions,
as seen with vitiligo and leukoderma. The photosensitizing
agents used in these ancient therapies have been characterised
with modern science as belonging to the psoralen family of
chemicals. Psoralens are still in use today in PDT regimes to
treat a variety of skin conditions, including vitiligo, psoriasis,
neurodermitis, eczema, cutaneous T-cell lymphoma, and
lichen ruber planus now called “PUVA-therapy” [10].
5. 20th Century Development of PDT
The first detailed scientific evidence that agents, photosensi-
tive synthetic dyes, in combination with a light source and
oxygen could have potential therapeutic effect was made
at the turn of the 20th century in the laboratory of von
Tappeiner in Munich, Germany. Historically this was a time
when Germany was leading the world in the industrial
synthesis of dyes.
While studying the effects of acridine on paramecia
cultures, Oscar Raab, a student of von Tappeiner observed
a toxic effect. Fortuitously Raab also observed that light was
responsible for the killing of paramecia cultures to take place.
Subsequent work in the laboratory of von Tappeiner showed
that oxygen was essential for the “photodynamic action”—a
term coined by von Tappeiner.
With the discovery of photodynamic effects, von
Tappeiner and colleagues went on to perform the first
PDT trial on patients with skin carcinoma using the
photosensitizer, eosin. Out of 6 patients with a facial basal
cell carcinoma, treated with a 1% eosin solution and a
long-term exposure either to sunlight or to arc-lamp light, 4
patients showed total tumour resolution and a relapse-free
period of 12 months.
It was only much later when Thomas Dougherty and
coworkers at Roswell Park Cancer Institute, Buffalo NY,
clinically tested PDT again. In 1978, they published striking
results in which they treated 113 cutaneous or subcutaneous
malignant tumors and observed a total or partial resolution
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of 111 tumors. The active photosensitizer used in the clinical
PDT trial by Dougherty was an agent called hematopor-
phyrin Derivative (HpD), which was first characterized in
1960 by Lipson. In his research, Lipson wanted to find a
diagnostic agent suitable for the detection of tumours in
patients. With the discovery of HpD, Lipson went onto
pioneering the use of endoscopes and HpD fluorescence to
detect tumours. As its name suggests, HpD is a porphyrin
species derived fromhematoporphyrin. Porphyrins have long
been considered as suitable agents for tumour photodiagnosis
and tumour PDT because cancerous cells exhibit a signifi-
cantly greater uptake and affinity for porphyrins compared to
normal quiescent tissues. This important observation, which
underlies the success of PDT to treat cancers, had been
established by a number of scientific researchers prior to the
discoveries made by Lipson. In 1924, Policard first revealed
the diagnostic capabilities of hematoporphyrin fluorescence
when he observed that ultraviolet radiation excited red
fluorescence in the sarcomas of laboratory rats. Policard
hypothesized at that time that the fluorescence was associated
with endogenous hematoporphyrin accumulation. In 1948,
Figge with coworkers showed on laboratory animals that
porphyrins exhibit a preferential affinity to rapidly dividing
cells, including malignant, embryonic, and regenerative cells,
and because of this, they proposed that porphyrins should be
used in the treatment of cancer. Subsequently many scientific
authors have repeated the observation that cancerous cells
naturally accumulate porphyrins and have characterised a
number of mechanisms to explain it.
HpD, under the pharmaceutical name Photofrin, was
the first PDT agent approved for clinical use in 1993 to
treat a form of bladder cancer in Canada. Over the next
decade, both PDT and the use of HpD received wider
international attention and grew in their clinical use, and lead
to the first PDT treatments to receive U.S. Food and Drug
Administration approval. Of all the nations beginning to use
PDT in the late 20th century, the Russians were the quickest
to advance its use clinically and to makemany developments.
Around this time, Russian scientists also collaborated with
NASAmedical scientists whowere looking at the use of LEDs
as more suitable light sources, compared to lasers, for PDT
applications. PDT has also seen considerable development in
Asia. Since 1990, the Chinese have been developing specialist
clinical expertise with PDT using their own domestically
produced photosensitizers, derived from hematoporphyrin,
and light sources. PDT in China is especially notable for the
technical skill of specialists in effecting resolution of difficult
to reach tumours [11].
6. Procedure
In order to achieve the selective destruction of the target area
using PDT while leaving normal tissues untouched, either
the photosensitizer can be applied locally to the target area
or photosensitive targets can be locally excited with light.
For instance, in the treatment of skin conditions, including
acne, psoriasis, and also skin cancers, the photosensitizer can
be applied topically and locally excited by a light source.
In the local treatment of internal tissues and cancers, after
photosensitizers have been administered intravenously, light
can be delivered to the target area using endoscopes and fiber
optic catheters. Photosensitizers can also target many viral
andmicrobial species, includingHIV andMRSA.Using PDT,
pathogens present in samples of blood and bone marrow can
be decontaminated before the samples are used further for
transfusions or transplants. PDT can also eradicate a wide
variety of pathogens of the skin and of the oral cavities.
Given the seriousness that drug resistant pathogens have
now become, there is increasing research into PDT as a new
antimicrobial therapy. Compared to normal tissues, most
types of cancers are especially active in both the uptake and
accumulation of photosensitizer agents, whichmakes cancers
especially vulnerable to PDT. Since photosensitizers can also
have a high affinity for vascular endothelial cells the net
result is both the direct tumor cell death and a shutdown of
the tumor vasculature. Therefore hypoxic regions of tumors
are insensitive to PDT. O
2
is the predominant actor of the
photokilling. PDT is intended to kill malignant cells, with
apoptotic or necrotic death and autophagy. It is not entirely
clear which pathways to cell death are more effective. As
new photosensitizer agents are developed an examination of
their localization patterns and photochemistrymay aid in the
selection of optimal agents for tumor eradication [3, 4, 8].
Methyl aminolevulinate (MAL) is a porphyrin precursor
approved for the treatment of actinic keratoses (AKs) of the
face and scalp [12–14].The approved protocol combines topi-
cal application of MAL to individual lesions under occlusion
for 3 hours followed by 37 J/cm2 of red light. PpIX is then
activated by red light, resulting in damage and killing of the
diseased cells. In order to simplify the treatment procedure
and improve tolerability, effect of daylight exposure was
observed [3, 15, 16]. Instead of fast activation of large amounts
of PpIX accumulated after occlusive treatment with MAL,
it was thought that continuous activation of PpIX during
its development might be just as efficient. The red and blue
light required to activate porphyrins are part of the daylight
spectrum. PDT treatment with daylight would make the
treatment much easier, as the patient would not have to
come back to the clinic after 3 h to be illuminated but we
would like to add that after almost 30 minutes under artificial
light patients can go under visible light and go back home.
The continuous activation of small amounts of PpIX could
possibly reduce treatment-related pain, which is the only
acute severe adverse effect of PDT [4, 5]. The aim of this
study was to compare conventional MAL-PDT using red
light-emitting diode (LED) lamps with MAL-PDT without
occlusive treatment and illumination with daylight, with the
primary endpoint being complete response rates of AK. The
adverse effects of the treatments were assessed as secondary
endpoints.
7. Treatment of NMSC
Internationally licensed for the treatment of NMSC, PDT is
indicated for superficial andmultiple lesions, especially in the
case of multifocal lesions, unclear lesion edges, risk of keloids
or surgical risk factors. Red light in BCC has a superior
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penetration compared to blue and green, although experience
is limited. Bowen disease has an effective result with good
cosmetic results as effective as 5-FU, imiquimod 5%, with
fewer side effects, as BCCs; nodular BCC < 2mm can be
effective, while insufficient evidence after SCC, which can
have Greater results with imiquimod 5%, excision and Mohs
surgery. For nBCCs 3 to 6 h of incubation are needed;
better results are seen combining different treatments, as
topical treatments, CO
2
laser, fractional laser, curettage, and
debulking 1 week before treatment and iron chelation (CP94)
to increase chelation of PpIX reducing its bioconversion to
heme, which is able to reduce tumor penetration. Pigmented
lesions respond poorly because of interference of melanin.
Many reports showed efficacy in the treatment of erythropla-
sia of Queyrat [17, 18].
8. Photorejuvenation
The visible signs of photodamage are characterized by wrin-
kling, coarse skin texture, pigmentation alterations, telang-
iectases, and case actinic keratosis (AKs). Intense pulsed
light (IPL) photorejuvenation has been shown to improve
each of the different components of photodamaged skin.
Photodynamic therapy with topical 5-aminolevulinic acid
(ALA-PDT) may be made also using IPL as a light source for
treatment of AK.They can therefore now be treated as part of
the photorejuvenation process rather than necessitating sepa-
rate topical therapywith 5-fluorouracil (5-FU) or cryotherapy
[19, 20].
9. Photosensitizer Licensed for Mild to
Moderate AKs on Face and Scalp
The effectiveness of PDT depends on the photosensitizer
used. New photosensitizer formulations have been developed
(i) Methyl aminolevulinate licensed in combinationwith
red light 570–670 nm for a total dose of 75 J/cm2
(metvix/Metvixia 16%) are not currently available in
USA.
(ii) ALA licensed in combination with blue light (levulan
kerastick 20%) approved for AK is the only agent
approved in USA. It is a hydrophilic, low molecular
weight molecule that is absorbed readily through
abnormal but not from normal keratin.
(iii) ALA Patch (Alacare, 4 cm2 containing 8mg ALA) is
recently licensed Europe.
Once ALA is absorbed by epidermal or appendage cells, it
is converted to PpIX, a potent photosensitizer. Due to of lim-
ited supplies of iron, a necessary catalyst for ferrochelatase,
recipient cells are unable to complete the final stage of
conversion of PpIX to heme, leading to PpIX accumulation.
With short application time (<4 hours) PpIX is largely
limited to the target site. Photosensitizer typically resolves
within 24 hours after application is completed. Maximal light
absorption is seen at 409 nm, and smaller peaks occur at
509 nm, 584 nm, and 625 nm. FDA approved 14- to 18-hour
application time; however studies have demonstrated efficacy
with shorter incubation period (1 h), more convenient for
patients and doctors. MAL is more lipophillic than ALA
and improved tumor tissue specificity while it was almost
similar for penetration. Except for Methyl aminolevulinate
the others are new formulations for AK treatment, with
different light sources. New indications (not yet approved)
are for actinic cheilitis, acral AK and AK in immunosuppred
patients, combination therapy for AK treatment [12, 18, 21].
10. New Concepts for Illumination
Are Being Investigated
Both ALA and MAL lead to the production of PpIX, which
displays a large peak in absorption spectra at 409 nm, with
much smaller peak at 509 nm, 584 nm, and 625 nm. While
blue light BluU (DUSA Pharmaceuticals, Wilmington, MA)
or Omnilux Blue (Photo Therapeutics Inc., Carlsbad, CA)
takes advantage of the largest absorption spike at 417 nm, it is
limited by depth of penetration to about 1.5 to 2mm.Red light
>600 nm requires higher energy levels to achieve the same
effect, but it is able to penetrate deeper (8–10mm). Filtered
red or green noncoherent light sources are commonly used
in Europe, whereas in USA longer wavelength light sources
include diode and pulsed dye lasers as well as intense pulsed
light (IPL) [16, 18].
5-ALA-patch for PDT of AK self-adhesive, skin coloured
ALA-Patch (2mg/cm2ALA) easy handling application in one
step, and built-in occlusion. There was no lesion preparation
on treatment session. Efficacy and side effects were com-
parable with other photosensitizers. Nano-emulsion-based
ALA formulation (BF-200) for AK phase III study using BF-
200 ALA (10% ALA in gel matrix to stabilize ALA and to
improve penetration); 3 h of incubation, illumination with
Aktilite (37 J/cm2 50–70mW/cm2), or Photodyn 750 (broad
band lamps 170 J/cm2), 1-2tx better efficacy. New concepts
for illumination are being investigated such as PDT of AK
using different incoherent light sourceswhichwere evaluated,
ALA, or MAL PDT with LED (633 ± 3 nm, 40 J/cm2) versus
incoherent lamp (580–700 nm, 100 J/cm2, 160mW/cm2); no
difference regarding efficacy, pain, patient satisfaction, and
cosmetic results was seen. MAL-PDT with red light (633 ±
3 nm, 37 J/cm2, 50mW/cm2) versus IPL (610–950 nm filtered
band piece 80 J/cm2), have no difference in term of efficacy
but significantly less pain with IPL. Gold standards are inco-
herent broadband lamps or LEDs; more studies are needed
to prove efficacy of IPL. MAL-PDT is not as effective for AK
on extremities, probably due to the absence of pilosebaceous
glands. PDT can be used as chemoprevention in transplanted
patients [22].
11. Limits of the Procedure
Tumour resistance and recurrence rates after PDT are how-
ever reported to range from 10 to 45%. Treatment fail-
ure in PDT is thought to be multifactorial, with insuffi-
cient tumour uptake of photosensitizer and PDT-induced
suppression of cutaneous antitumour responses, potentially
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important contributors for incomplete tumour killing [23].
Antitumour immunity plays a key role in reducing skin
cancer development and also in skin cancer treatment
responses. Immune-suppressed organ transplant recipients
have significantly higher PDT failure rates compared with
immunocompetent controls.The immune suppressive effects
of PDT have been reported in mice and recently in humans.
At the light doses and irradiance rates in current clinical
use, topical PDT causes significant suppression of delayed-
type hypersensitivity responses to recall antigens and depletes
Langerhans cells in both normal human skin and within
BCCs.The immune effects of PDT are sensitive to changes in
irradiance rate; while light delivered at a high irradiance rate
(approximately 75mWcm) as in clinical practice is highly
immune suppressive, delivery of the same total light dose at
a lower irradiance rate (15mWcm) does not cause significant
immune suppression in healthy volunteers. Oxidative DNA
photolesions, observed in ex vivo human skin after high,
but not low irradiance rate PDT, may be a key trigger of
PDT-induced immunosuppression. The main disadvantage
of PDT is that it can be painful, limiting its applicability
[18, 24], which can be due to PpIX concentration, fluence rate,
wavelength, treatment area size, location, sex, photosensitizer
used, skin type, age, and lesion type. Pain is the major draw-
back of photodynamic therapy (PDT), an otherwise effective
treatment for actinic keratoses (AKs). Pain is a frequent side
effect of PDT. It is largely unpredictable and amajor drawback
of the treatment. It varies from patient to patient and the
experience of burning, stinging, and prickling sensation
ranges from mild to severe. In order to find the best pain
prevention, investigators have tried to identify susceptible
patients. In the last decade especially, there has been a spate
of articles concerned with pain and PDT. Various factors
have been identified to have influence on pain, but none
of them has been consistently reported in all publications.
Pain during PDT is associated with AK location and size.
Treatment of bigger lesions (>130mm2) results in more pain
than smaller ones and treatment of the face is more painful
than the scalp area. It is explained by tissue hypoxia and/or
singlet oxygen generation, increasing the amount of pain
experienced during PDT. However, other studies support our
findings that the beginning of the procedure is most painful
and pain is more intensive during the first procedure than
during the second [24]. Pain diminution might be explained
by desensitization of nociceptors, acclimatization to the treat-
ment situation, or decreasing levels of photosensitizer during
the treatment. This would indicate that pain is related to the
photodynamic process itself in a time and dose dependent
fashion [25]. Usually no association between the pain and
the treatment dose are observed. Though Radakovic-Fijan
observed a trend toward higher doses causing more pain,
the finding was not statistically significant. Photodynamic
therapy (PDT) is an effective but time-consuming and often
painful treatment for NMSC. Daylight is the combination
of direct and diffuse sunlight outdoors during daytime [15,
25]. The spectrum of electromagnetic radiation striking the
earth’s atmosphere is the ultraviolet light ranging from 1000
to 380 nm, visible light from 380 to 780 nm, and infrared
light ranging from 780 nm to 106 nm. Home-based daylight-
PDT has the potential to facilitate treatment procedure and
to reduce associated pain due to continuous activation of
small amounts of porphyrins. Moreover, a reduced methyl
aminolevulinate (MAL) concentrationmay reduce associated
inflammation, making the treatment more tolerable for the
patients. The procedure is characterized by curettage of
lesions, application of medium (20–30 SPF) sun block, or
photolyase inhibitors on the whole exposed area both treated
and untreated; ask the patient to wait in an artificial light
place for 20–30 minutes and then go under daylight from
1.5 to 2.5 hours, or the whole day under sunlight, then wash
off the cream with thermal spring water, from the treated
area, apply a pain relief cream exactly after PDT, and go on
twice daily for 10 to 20 days, to reduce itching and burning
sensation. Home-based daylight-mediatedMAL-PDTwas an
effective and well-tolerated treatment in sun exposed areas.
Pain is the major drawback of photodynamic therapy (PDT),
an otherwise effective treatment for actinic keratoses (AKs).
Pain during PDT is associated with AK location and size.
PDT performed following MAL application to the entire
face is not only more convenient but offers the potential
of preventing new AKs. In order to simplify the treatment
procedure and improve tolerability, effect of daylight expo-
sure was observed [15]. Instead of fast activation of large
amounts of PpIX accumulated after occlusive treatment with
MAL, it was thought that continuous activation of PpIX
during its development might be just as efficient. The red
and blue light required to activate porphyrins are part of
the daylight spectrum. PDT treatment with daylight would
make the treatment much easier, as the patient would not
have to come back to the clinic after 3 h to be illuminated
but they can just go under visible light after almost 30
minutes. The continuous activation of small amounts of
PpIX could possibly reduce treatment-related pain, which is
the only acute severe adverse effect of PDT. Daylight-PDT
would make the treatment independent of the clinic and less
painful due to the continuous activation of small amounts of
porphyrins during its formation. Due to the high incidence
and the potential of the AK to become invasive SCC it is
important to treat all of them and that their treatment be
not only effective but also uncomplicated, without side effects
and with good cosmetic results [21, 26]. With these results,
clinicians can identify patients most likely to experience
pain to provide them with timely and adequate pain-control
approaches during PDT or personalize treatments according
to age, gender, Fitzpatrick skin type, size, clinical grade and
location of the AK, pretreatment fluorescence intensity, and
the red light dose during the ALA-PDT for AKs treated on
the face and scalp. The immune suppressive effects of topical
photodynamic therapy (PDT) are potential contributors to
treatment failure after PDT for nonmelanoma skin cancer.
Nicotinamide (vitamin B3) prevents immune suppression
by ultraviolet radiation, but its effects on PDT-induced
immunosuppression are unknown. While the clinical rele-
vance of these findings is currently unknown, nicotinamide
may provide an inexpensive means of preventing PDT-
induced immune suppression and enhancing PDT cure
rates. Oral nicotinamide is well tolerated even at high doses
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(up to approximately 3/5 g per day) with a lack of reported
side effects. It can be considered as an inexpensive, conve-
nient, and nontoxic agent for skin cancer chemoprevention
[27].
New chemopreventive agents that can be used to comple-
ment sunscreens may result in decreased incidence, morbid-
ity, and mortality of skin cancer. Therefore, further research
is urgently required to find an ideal chemopreventive agent
that is effective, safe, accessible, and convenient either topical
or systemical.
12. Conclusion
NMSC, with their rapidly growing incidence, negatively
influence quality of life; some of them can develop in more
aggressive tumor, and therefore all of them need to be
treated.Their treatment needs to be efficacious and easy to be
performed. PDT is a safe and effective noninvasive treatment;
MAL or ALA is an attractive, well established and approved,
single day therapy for mild to moderate AK, actinic cheilitis,
and superficial BCC (especially of the eyelid) on face, scalp,
and some SCC [15, 24]. PDT may be the first treatment
choice for multiple AK or field cancerisation on face and
scalp with additional photorejuvenation effects. ALA-PDT
using IPL as a light source is an effective treatment for both
photorejuvenation and AKs [12]. For hypertrophic lesions a
keratolityc agent applied before treatment and the curettage
of lesions may help in improving absorption. However the
conventional type is associated with inconveniently long
clinic visits and discomfort during therapy; this may ride out
with daylight mediated PDT, which is a simpler and more
tolerable treatment procedure; it is nearly pain-free andmore
pleasant for both patients and physicians, especially for sun-
exposed areas where there are multiple lesions, independent
of the weather conditions [15, 16]. As BCC and nodular BCC
are thicker lesions than AKs, the effective daylight dose,
which effectively treats AK, might not provide enough red
light to ensure effective activation of PpIX in the deeper part
of the lesion, probably leaving MAL-PDT under occlusion
for more than 5 hours especially on special anatomical
area as periocular one and may lead to a higher local skin
reaction, with consequent better results. As daylight PDT is
nearly pain-free it is possible to treat larger areas than with
conventional type; the clinical attendance is much shorter
making the clinicians able to visit and treat more patients
[21, 26]. Further studies will be needed to understand ideal
condition of daylight PDT, for instance season, time, outdoor
temperature, duration, geographical condition, and kind of
lesions.
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